Skip to content

A Study to Evaluate ALN-HTT02 in Adult Patients with Huntington’s Disease

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-515732-68-00
Acronym
ALN-HTT02-001
Enrollment
15
Registered
2024-12-23
Start date
2025-03-07
Completion date
Unknown
Last updated
2025-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Huntington’s disease

Interventions

None listed

Sponsors

Alnylam Pharmaceuticals Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026